Neu Health is dedicated to making the latest Parkinson’s disease and dementia care accessible for all. Neu Health has developed a digital platform for clinicians to drive better clinical outcomes and quality of life. Using a mobile app, connected to an AI-driven clinical decision support tool, Neu Health is closing the care management and data gap between clinic visits. Leveraging 10 years of longitudinal clinical data, research and validation by leading neuroscientists at the University of Oxford, Neu Health is helping clinicians, care givers, and patients to tackle Parkinson’s and dementia.
Dementia, Parkinson’s disease and other neurodegenerative conditions are growing fast and becoming the biggest causes of mortality and morbidity. Despite the large number of people and huge predicted growth, clinicians have few tools to support people living with these conditions today. Neu Health has built 'Neu Platform' which is comprised of a patient facing app, cloud machine learning (ML) platform and front-end clinician web app. The initial intended use is if for patients with mild to moderate Parkinson’s disease. This app comprises a battery of 7 motor tests completed on a smart phone that allow estimation of clinical scores and risk prediction of clinical outcomes 18 months in advance. This information is displayed on a web app viewed by the clinical team who then use this information to better understand patient disease and allow more informed clinical decisions. In addition to the core ML motor task components of the platform, there are other platform features that include medication diary and alerts, educational resources, patient recorded symptom tracking, and visualisation of scores that are displayed back to the patient and the clinical teams. The Platform aims to 1) Improve medication management, 2) Identify risk of future clinical outcomes, 3) Provide educational resources relevant to patient condition, 4) Assist clinicians in their decision-making regarding patient needs and available therapies, 5) Help clinicians in the evaluation of Parkinsonism and responsiveness to therapeuticinterventions, and 6) Remotely record and monitor patient progression. Future versions of the Platform will include new algorithms to measure cognitive decline for intended use with people with dementia.